Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

AstraZeneca PLC (NYSE:AZN)

31.13
Delayed Data
As of Jul 22
 +0.60 / +1.97%
Today’s Change
26.97
Today|||52-Week Range
34.88
-8.31%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Major
MARKET CAP
$78.7B

Company Description

AstraZeneca Plc is a global research-based biopharmaceutical company, which primarily focuses on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. The company sells products under the brands Atacand, Crestor, Onglyza, Nexium, Entocort, Losec, Merrem/Meronem, Carbocaine, Citanest, Diprivan, Marcaine/Sensorcaine. AstraZeneca was founded on April 6, 1999 and is headquartered in London, the United Kingdom.

Contact Information

AstraZeneca Plc
2 Kingdom Street
London Greater London W2 6BD
P:442076048000
Investor Relations:
442076048199

Employees

Shareholders

Mutual fund holders5.58%
Other institutional4.64%
Individual stakeholders--

Top Executives

Pascal SoriotChief Executive Officer & Executive Director
Pam P. ChengExecutive VP-Operations & Information Technology
Marc DunoyerChief Financial Officer & Executive Director
Sean BohenChief Medical Officer & Executive Vice President
Edward BradleySenior VP-Research & Development